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Abstract
Bipolar disorders rank as one of the most disabling illnesses in working age adults worldwide. Despite this, the
quality of care offered to patients with this disorder is suboptimal, largely due to limitations in our understanding of
the pathology. Improving this scenario requires the development of a critical mass of expertise and multicentre
collaborative projects. Within the framework of the European FP7 programme, we developed a European Network
of Bipolar Research Expert Centres (ENBREC) designed specifically to facilitate EU-wide studies. ENBREC provides an
integrated support structure facilitating research on disease mechanisms and clinical outcomes across six European
countries (France, Germany, Italy, Norway, Spain and the UK). The centres are adopting a standardised clinical
assessment that explores multiple aspects of bipolar disorder through a structured evaluation designed to inform
clinical decision-making as well as being applicable to research. Reliable, established measures have been
prioritised, and instruments have been translated and validated when necessary. An electronic healthcare record
and monitoring system (e-ENBREC©) has been developed to collate the data. Protocols to conduct multicentre
clinical observational studies and joint studies on cognitive function, biomarkers, genetics, and neuroimaging are in
progress; a pilot study has been completed on strategies for routine implementation of psycho-education. The
network demonstrates ‘proof of principle’ that expert centres across Europe can collaborate on a wide range of
basic science and clinical programmes using shared protocols. This paper is to describe the network and how it
aims to improve the quality and effectiveness of research in a neglected priority area.
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Background
Bipolar disorders (BD) are characterised by recurrent
manic and depressive episodes that usually commence
in early adulthood and affect 1% to 4% of the general
population (Merikangas et al. 2007). According to the
World Health Organization study on global burden
of disease, BD are ranked sixth amongst the most
disabling illnesses in working age adults worldwide
(above schizophrenia which is ranked eighth) (Lopez and
Murray 1998) - findings that are reinforced by the recent
European study on the burden of mental health (Olesen
et al. 2012).
Despite its high prevalence, BD is often unrecognised or
misdiagnosed leading to inappropriate or delayed treat-
ments, with significant and devastating health and social
consequences (Baca-Garcia et al. 2007; Hirschfeld et al.
2003; Scott and Leboyer 2012). Even when the diagnosis is
established, it is clear that the management of BD is a
major challenge, and surveys confirm that suboptimal treat-
ment is a common concern across Europe (Scott et al.
2006). The significant disease burden attributable to BD is
amplified by additional, often multiple psychiatric and
physical comorbidities, and premature mortality (Leboyer
and Kupfer 2010). The reduced life expectancy in BD
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due to medical comorbidity and adverse lifestyles is
about 10 years for men and 11 for women (Chang et al.
2011). Furthermore, rates of completed suicide have gen-
erally been estimated to be between 10% and 20%
(Müller-Oerlinghausen et al. 2002). Even if recent studies
are more optimistic, rates in BD exceed unipolar depres-
sion and schizophrenia (Bostwick and Pankratz 2000;
Dutta et al. 2007).
Whilst adherence to clinical practice guideline recom-
mendations can improve outcome for patients (Goodwin
et al. 2009; Nivoli et al. 2011a, b), many of the algorithms
for BD patients are derived from efficacy data from
randomised controlled clinical trials (RCTs). Such RCTs
usually recruit homogeneous samples of patients who will
represent only about 20% of the BD population treated in
day-to-day clinical practice (Vieta and Cruz 2012). Also,
guidelines are not consistent in their recommendations,
differing in their advice on when to use adjunctive psycho-
logical therapies or which type of therapy to offer to differ-
ent patient subpopulations (Henry et al. 2011). As a
consequence, clinicians often find it difficult to sys-
tematically apply recommendations to individual cases. For
example, many guidelines suggest monotherapy as main-
tenance treatment (based on findings from RCTs); the clin-
ical reality is that many patients receive polypharmacy
for mood stabilisation (Frye et al. 2000; Wolfsperger
et al. 2007). Other strategies, extending beyond the use of
guidelines, therefore need to be examined, especially be-
cause the evidence suggests that efforts made to spread
good clinical practice invariably result in gains for pa-
tients. For example, Bauer et al. (2009) have shown that
promoting systematic assessments and offering local sup-
port to clinicians working with BD improve patient out-
comes. Similar national initiatives are being undertaken,
e.g. the French BD network developed by Fondation
FondaMental (Henry et al. 2011) and the CIBERSAM
in Spain (Vieta 2011). However, to date, there have been
few attempts to facilitate an international programme on
the translation of research knowledge into evidence-based
clinical practice. This is especially likely to be benefi-
cial in multifaceted disorders such as BD, where a
‘personalised medicine’ approach represents the best way
to take into account the diversity of clinical presentation,
including the frequent presence of comorbidities, and the
range and optimal combinations of pharmacological and
psychosocial treatments (Scott 2011).
The nature and complexity of BD mean that successful
translational research requires the integration of advances
in clinical and basic science to develop targeted treatments
that are more specific for BD. However, improving research
in the field of severe and complex disorders increasingly re-
quires the development of a critical mass of expertise
through broadly based collaborative networks. Multicentre
projects maximise the likelihood of recruitment of large
clinical cohorts that reflect the heterogeneity of the disorder
and facilitate cross-national epidemiological studies, as well
as providing subgroups with adequate statistical power to
explore pathophysiological and gene-environment interac-
tions and to conduct clinical trials. This type of research is
only usually achievable through the development and im-
plementation of shared research protocols across a large
number of centres (Vieta et al. 2011).
In order to disseminate systematic clinical assessment
and high quality treatment protocols and to foster re-
search to improve the management of BD and to develop
a better understanding of the mechanisms underlying
this complex condition, we have developed a network of
bipolar expert centre at a European level: European
Network of Bipolar Research Expert Centre (ENBREC,
www.enbrec.eu). This network was set up via FP7
funding but is maintained through the support from
the European College of Neuropsychopharmacology
(ECNP) network initiative (ECNP-NI). In this paper, we de-
scribe the development of the ENBREC network and the
common, cross-national clinical and research tools we
are introducing.
Results and discussion
In 2009, the European Union resolution on Mental Health
(EU parliament A6-0034-2009) highlighted the need to de-
velop comprehensive and integrated mental health strat-
egies in Europe, such as cohort studies. As we live in a
globally competitive environment, it is fundamental for
Europe's success that high level research is viewed as a pri-
ority. This will demand joint responses from member states
and between-country collaborations so that expertise and
experience can be shared, and benefits can be rapidly dis-
seminated on a Europe-wide basis. The EU resolution also
acknowledges that the only way to diminish the cost and
burden of mental disorders in the long-term is to invest re-
sources in research to improve early diagnosis, develop in-
novative treatments, and to attempt to identify individuals
at high risk of developing mental disorders with the ultim-
ate goal of implementing prevention strategies. The ECNP
is also concerned to support the development of independ-
ent collaborative international research networks of basic
scientists and practising clinicians within Europe, and has
established the ECNP-NI to help meet this goal. The aims
and activities of its component networks are determined by
the experience and expertise of the participating members,
but each has the goal of extending current understanding
of the causes and treatment of central nervous system dis-
orders, thereby contributing to improvements in clinical
outcomes and reducing the societal burden of mental and
neurodegenerative disorders. Given the aspirations of these
organisations, it is understandable that both have supported
the development and activities of ENBREC. There is a need
for a coordinated approach to developing patient
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cohorts for the more prevalent mental disorders
representing major mental health challenges such as BD. In
this context, integrated research programmes are clearly
useful as clinical, epidemiological and cognitive data can be
combined with biological studies such as brain imaging,
genetics or neurobiology.
Expert centres provide a unified setting for high-
quality care and research (Henry et al. 2011; Vieta 2011).
Such expert centres have been shown to improve outcome
of bipolar disorder compared to standard care (Kessing
et al. 2013).
We believe that embedding cohort studies within our
collaborative network is the most efficient approach to
obtain cross-sectional and longitudinal information about
BD. The clinical setting of participating centres will also
allow speedy implementation of improved diagnostic and
assessment strategies. Whilst a deeper knowledge of the
pathophysiology of mental health is required to improve
the management of diseases and the development of
new treatments, the programme will strengthen transla-
tional research delivering a new, broad, comprehensive
understanding of BD from basic science to biomedical re-
search. The ultimate clinical aim of ENBREC is to develop
personalised medicine, aspiring to assess each patient using
a spectrum of behavioural and neurobiological measures in
order to define the best therapeutic strategies relevant to a
particular profile of the disorder. Implementing prevention,
early diagnosis and personalised interventions will allow
ENBREC to demonstrate ways to improve personal and
economic outcomes of mental health care.
This network offers a ‘proof of principle’ that expert
centres across Europe can undertake collaborative stud-
ies using shared assessment protocols. The purpose of
this network is to improve the quality and efficiency of
research in the neglected priority area of mental health,
specifically mood disorder.
This type of collaborative project can have a positive
impact on attitudes and can bring together individuals
who actively seek opportunities for collaboration. This
project both supports existing collaborations and helps
create new ones. This is of utmost importance for gen-
eral psychiatry and for BD research. In spite of the major
burden of disease for the society, mental health re-
search as a whole (and BD research in particular) is
currently hampered by several gaps. These include a
gap in structuring due to its cross-disciplinary nature,
encompassing a broad range of disciplines from psych-
ology to molecular biology, a gap in funding, as a re-
sult of the poor structuring of mental health research
at the national and European level, and a gap in met
and unmet clinical needs, because research priorities
are not always translated into clinical advances in a




Following a successful application to the ‘Support Action’
call of the European FP7 programme in 2009, we set about
developing the infrastructure for ENBREC, a disease-
oriented EU-wide network designed to foster multi-
national collaboration among centres with expertise in the
clinical management of and/or research in BD. The
programme has now evolved into one of the networks
supported by the ECNP. For Europe, the added value of
ENBREC is that expertise in different research fields in-
cluding epidemiology, genetics and clinical trial design is
shared across centres and that leading researchers in the
field of BD gain early access to large patient cohorts, im-
proving the clinical representativeness of research samples
and enhancing the external validity and statistical power
of proposed studies. A core goal of ENBREC is to establish
connections between leading centres in the field and to
foster the development of or support existing national net-
works, with some of the national centres being incorpo-
rated into the Europe-wide network.
From a clinical perspective, the goal of ENBREC is to
develop assessment tools and procedures to improve the
diagnosis and management of BD. In addition, the cross-
centre links enhance clinical investigations and observa-
tional studies, which benefit from the pooling of relevant
resources including access to patients. To achieve this,
there was first a need for centres to work together to de-
velop a common assessment protocol and to develop
mechanisms for efficient sharing of clinical data and
biomaterial.
A separate but linked goal for the network is to dis-
seminate clinical and basic research ideas to others
working in BD in Europe and elsewhere and to produce
consensus papers that highlight how to translate re-
search findings into improved health care and clinical
practice. The network also offers an unrivalled oppor-
tunity to undertake joint training of the next generation
of researchers and clinicians wishing to develop expert-
ise in BD, and joint applications for postgraduate train-
ing have been produced.
Participants and organisation
Six European countries are currently involved in the net-
work (France, Germany, Italy, Norway, Spain and the
UK) with a maximum of two centres per country. The
coordinator (Chantal Henry, France) is in charge for
day-to-day management of the ENBREC network, whilst
the ENBREC project committee, composed of one repre-
sentative for each country, determines the overall direc-
tion and work of the network. The programme of work
is divided into work-packages (WPs) organised by a WP
leader (Table 1).
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A standardised assessment package
All centres are in the process of adopting the same
evaluation package, with many having already achieved
full implementation (Henry et al. 2011). The package
comprises a wide-ranging psychobiosocial assessment
that systematically explores all aspects of BD including
clinical presentation, personal history and factors that
potentially influence the course and outcome of BD. The
measures provide a high quality, structured evaluation
that can inform clinical decision making, but the tools
selected are also relevant and applicable to research pro-
jects. Valid, reliable and established observer- and self-
rating scales were chosen in preference to idiosyncratic
or untested measures. Where appropriate, assessment
tools were translated into different languages, and valid-
ation studies have been undertaken as required.
Clinical data
Agreement was reached on a core set of pre-existing rating
scales that will be used for establishing diagnosis, evaluating
symptoms, assessing functioning and collecting patient-
reported data (Table 2). As well as established and nation-
ally validated measures, some new instruments are also be-
ing ‘trialled’ in selected centres. For example, in Spain, a
dimensional assessment for BD, the Dimensional Assess-
ment of Mental Nosology for DSM, has been developed to
explore trans-diagnostic aspects of symptom evaluation
(see Vieta and Phillips 2007).
Polarity, duration and severity are carefully evaluated
for the current presentation whether the symptoms
reach syndromal criteria or are or subsyndromal. This in-
formation is supplemented by data on the initial clinical
presentation (including age of onset of the first symptoms,
age of onset and polarity of first mood episode, age of first
psychotropic treatment and age at first hospitalisation). De-
tails of the total number of manic and total number of de-
pressive episodes, number of hospitalisations, the presence
or absence of rapid cycling, and occurrence of any postpar-
tum episodes and predominant polarity (Colom et al. 2006)
are also recorded. Psychiatric and medical comorbidities
are also recorded, as are any history of suicide attempts and
family history of mental disorders.
Past and current pharmacological treatments with psy-
chotropic drugs are documented in the evaluation, with
class of drug, dosage and duration of each treatment.
Adherence to treatment (ranked globally as good, mod-
erate or poor) is also recorded, as well as the degree of
improvement with current treatment. Other previous
treatments are also documented, including details of
physical treatments, (such as electroconvulsive therapy
or trans-cranial magnetic stimulation) and psychosocial
interventions (such as cognitive-behavioural therapy,
interpersonal therapy and individual or family psycho-
education). Physical measurements at inclusion include
metrics (height, weight and abdominal perimeter), vital
Table 1 Work packages supported by the ENBREC network
Work package Scope Lead
WP1 Management of the project Chantal Henry, France
WP2 Developing common tools for diagnosis and multinational cohort follow-up Eduard Vieta, Spain
WP3 Developing common tools for neurocognitive assessment Guy Goodwin, UK
WP4 Assessment of common biomarkers and genetic markers Marion Leboyer, France
WP5 Development of standards for imaging Ole Andreassen, Norway
WP6 Treatment optimization, definition of subgroups of responders Michael Bauer, Germany
WP7 Supporting multinational clinical research and data management Jacques Demotes, France
WP8 Education, information, dissemination, translation of research outcomes into healthcare Angelo Barbato, Italy
WP9a Pan-European educational programme - ‘Improving the identification of BD II disorders’ Jan Scott, UK
WP9b Extension to new countries and within the countries Jacques Demotes, France
Table 2 Core clinical rating scales
Rating scales Reference
Psychiatric diagnosis
Structured Clinical Interview for DSM-IV
Axis I Disorders
First et al. 2002
or Mini-International Neuropsychiatric
Interview
Sheehan et al. 1998
Clinical Global Impression-Bipolar Version
- Modified





Young Mania Rating Scale Young et al. 1978
Functioning
Global Assessment of Functioning Scale American Psychiatric
Association 2000
Functioning Assessment Short Test Rosa et al. 2007
Self-rating scales for patients
State-Trait Anxiety Inventory Marteau and Bekker 1992
Altman Self-Rating Scale for Mania Altman et al. 1997
Quick Inventory of Depressive
Symptomatology
Rush et al. 2003
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signs (blood pressure and heart rate) and a full blood
and biochemistry work-up.
Neurocognitive data
The major issues for the network with regard to the rou-
tine use of neurocognitive testing were the lengthy and
time-consuming nature of assessments and the lack of
feasibility of their use in a multidimensional assessment
package (Goodwin et al. 2008). Therefore, ENBREC
members who are experts on neurocognition reviewed
the current literature on BD and cognitive impairment
and, from this, devised a minimum cognitive battery for
inclusion in e-ENBREC. The selected tests include a ver-
bal learning and memory assessment (based on California
Verbal Learning Test), Forward and Reverse Digit Span
(from WAIS-R Digit Span), and Trail Making Test A and
B. These tests are expected to provide robust measures of
cognitive functioning in BD patients across several do-
mains and will allow deficits to be identified and moni-
tored over time as the illness progresses and/or new
treatments are developed. ENBREC findings suggest a re-
lationship between cognitive impairment and treatment
adherence (Martinez-Aran et al. 2009).
Data collection: electronic records and shared database
It is important for multisite collaborations that involve
simultaneous collation of assessments to have efficient
procedures for data capture that do not overburden cli-
nicians or researchers but that maximise the likelihood
of complete and accurate data entry. To help in this
process, a specific case report form was produced, in-
corporating all the items in the standardised assessment
package which was then translated into the languages of
participating countries for local use.
A web-based application, e-ENBREC©, has also been
developed to collate assessment data for clinical monitor-
ing and research purposes. Access to the system is care-
fully regulated, and approval has to be obtained from the
committee in charge of the safety of computerised data-
bases in each country. To optimise data entry and retrieval,
free text input has been minimised, and drop-down lists
and other approaches leading to standardised inputs have
been chosen whenever possible. The XML format is used
to transfer data from e-ENBREC©(European network of bi-
polar research) expert centre into an anonymised common
database for research purpose.
Specific research projects
In addition to the core clinical and cognitive datasets
being documented for clinical cases, specific data sets
are being developed for research or diagnostic pur-
poses in participating countries. These can be linked
to the clinical database in order to allow network-
wide evaluation and, thus, increase the statistical
power of basic science studies. Examples of these
include:
(a)Collection of DNA
The aim of this project is to collect samples of
biomaterial to perform genetic and biomarker
studies. This will enable the collection of large DNA
samples from patients who have been well
characterised from a clinical, cognitive and,
potentially, imaging perspective. The analysis of
more homogenous patient groups with well-
specified clinical features should facilitate the
identification of potential genetic markers of BD.
Existing procedures already allow ENBREC partners
to exchange biological material. The Material
Transfer Agreement has already been used for this
purpose by ENBREC partners.
(b)Brain imaging
Brain imaging techniques have revolutionised the
understanding of the human brain, with potential to
identify brain pathology underlying psychiatric
disorders, including bipolar disorders (Rimol et al.
2010). In addition, it has the potential to become a
tool for early identification, subgrouping, disease
monitoring and treatment stratification. The overall
aim of the ENBREC project is to develop a common
MRI protocol which allows pooling of data acquired
with standard clinical MRI scanners that can be
used in multisite studies of bipolar disorders.
Structural MRI studies usually provide global
estimates of gray or white matter volume changes,
or a small number of regions of interest. Recent
advances in structural imaging now allow for a more
comprehensive evaluation of brain changes by
providing continuous maps of cortical thickness and
surface area, subcortical volumes and measures of
white matter microstructure throughout the brain
(Fischl and Dale 2000). White matter can now be
quantified using diffusion tensor imaging. It will be
important to cross this information with cognitive
data in large cohorts of patients in order to address
any structural features underlying the pathology
(Forcada et al. 2011). In the future and if funding
permits, it is hoped to extend the imaging protocols
of functional MRI.
Promoting innovative care and treatment protocols
A significant number of patients with BD, who achieve
neither clinical remission nor functional recovery despite
high levels of medication adherence (Rosa et al. 2011) and
recurrence rates following a manic episode, are about 40%
to 60% even when receiving maintenance drug therapy
(Gitlin et al. 1995). Such data highlight the need to address
nonpharmacological factors in order to improve outcome
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and to encourage patients to take an active role in the man-
agement of their illness and collaborate in the care process.
Surveys of patient preferences reveal that there is a strong
wish by patients with BD to undertake self-help and partici-
pate in psychological interventions (Pontin et al. 2009).
Evidence from research supports the efficacy and likely
effectiveness of a number of psychosocial treatments, in-
cluding group psycho-education, family-focused therapy,
interpersonal and social rhythm therapy, and cognitive
behaviour therapy (Miklowitz and Scott 2009; Vieta
et al. 2009). The lower cost and potential ease of dissem-
ination of group psycho-education suggest that its use as
a first-line approach warrants exploration. Research by
members of ENBREC suggests that a number of ele-
ments should ideally be included in a basic psycho-
education package. The key elements of the package and
options for delivery such as 11 sessions of group psycho-
education supplemented by a DVD, and an abbreviated
psycho-education package, are currently being explored
by ENBREC centres. The recommended components of
a basic psycho-education package are the following:
(a)Use of a mood diary and life-event charting to
monitor mood patterns and effectiveness of
intervention
(b)Awareness of medication effects and improvement
of decision-making skills on drug treatment in a
collaborative way
(c) Identification of early warning signs
(d)Encouragement of structured routines and healthy
lifestyles
(e)Stabilisation of sleep/wake cycles
(f ) Emotional self-regulation and social skills
(g)Improvement of communication skills
(h)Acquisition of balanced attitudes towards the self in
relation to the illness
(i) Reduction of self-stigmatisation
Despite promising research findings, dissemination re-
mains an unresolved issue. Within the ENBREC network, a
working group has been mandated to recommend how best
to extend psycho-education techniques that have been
shown to be effective into every level of everyday psychi-
atric care.
Sustainability of the network: links maintained beyond
initial phase of ENBREC
By the time the FP7 funding ended (June 2011), ENBREC
members had engaged in and continue to be involved in
several joint research projects at a Europe-wide level. The
ongoing support of ECNP-NI is also vital to the continu-
ation of the collaborative group. The sustainability of the
network is secured because the centres involved in the col-
laboration are all clinically active, offering expert care and
treatment of BD. Resources are provided within each coun-
try to ensure continuity of clinical care. The common clin-
ical and cognitive assessment and the follow-up protocol
chosen for ENBREC represent a basic, but systematic and
comprehensive assessment of cases which allows the expert
centres to provide high-quality advice on diagnosis and
treatment to the referrers and patients in each participating
country. At the same time, a major potential barrier to
cross-national research has been overcome, allowing easier
implementation of new basic science and clinical research
studies in the future. The closely identified research group
will also be in a strong position to apply for multicentre re-
search grants and potentially represents an attractive option
to international industrial partners who, for example, wish
to plan and execute pilot studies or pivotal randomised
controlled clinical trials. Industry-funded unrestricted edu-
cational grants are also being explored to help support the
training initiatives that have grown out of the research
programme.
Conclusions
Currently, there is no equivalent multisite collaboration
in the field of BD in Europe, which is able to conduct re-
search within an organised disease-oriented clinical net-
work, including multidisciplinary and trans-cultural
approaches and with a long-term perspective. The net-
work will provide useful clinical data from a European
sample of patients. A major strength of the network is
its capacity to develop research from basic science to
psychosocial research programmes. It also contributes to
the ECNP-NI portfolio. In the near future, the efforts of
multiple stakeholders, promoters and funding agencies
will need to converge into more efficient and coordi-
nated initiatives under the umbrella and support of ‘net-
works of networks’, which should avoid redundancies
and inefficiencies in research. ENBREC may be the seed
of such a Network in the field of BD.
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